Available in Colombia, Chile, Peru, Brazil, Argentina, Mexico
This is a Phase III randomized, double-blind, parallel group, multi-center event-driven
study comparing BGF MDI 320/14.4/9.6 μg BID with GFF MDI 14.4/9.6 μg BID in participants
with COPD who are at risk of a cardiopulmonary event.
13Research sites
5000Patients around the world